Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AAPG

Ascentage Pharma Group International ADR

Dec 12 • 04:00PM ET

30.35

+0.36 1.20 %

Healthcare • Biotechnology • China • NASD

Index	-	P/E	-	EPS (ttm)	-2.01	Insider Own	-	Shs Outstand	52.23M	Perf Week	-7.69%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	-	Shs Float	-	Perf Month	-5.27%
Enterprise Value	2.82B	PEG	-	EPS next Q	-0.42	Inst Own	0.10%	Short Float	-	Perf Quarter	-24.99%
Income	-160.62M	P/S	52.08	EPS this Y	-21.18%	Inst Trans	1.47%	Short Ratio	0.23	Perf Half Y	-5.22%
Sales	54.07M	P/B	28.31	EPS next Y	48.17%	ROA	-37.67%	Short Interest	0.00M	Perf YTD	74.63%
Book/sh	1.07	P/C	12.14	EPS next 5Y	25.69%	ROE	-161.90%	52W High	48.45 -37.36%	Perf Year	-
Cash/sh	2.50	P/FCF	-	EPS past 3/5Y	26.85% 36.70%	ROIC	-74.33%	52W Low	16.50 83.94%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	215.77% 130.37%	Gross Margin	70.27%	Volatility	2.42% 2.59%	Perf 5Y	-
Dividend TTM	-	EV/Sales	52.24	EPS Y/Y TTM	-191.46%	Oper. Margin	-287.25%	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.53	Sales Y/Y TTM	-56.78%	Profit Margin	-297.05%	RSI (14)	42.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	-	SMA20	-4.16%	Beta	-	Target Price	48.20
Payout	-	Debt/Eq	2.58	Sales Q/Q	-	SMA50	-10.01%	Rel Volume	0.09	Prev Close	29.99
Employees	567	LT Debt/Eq	1.32	Earnings	Aug 20 AMC	SMA200	-5.12%	Avg Volume	6.85K	Price	30.35
IPO	Jan 27, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	639	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Initiated	Oppenheimer	Outperform	$45
Nov-24-25	Initiated	Truist	Buy
Nov-10-25	Initiated	BTIG Research	Buy	$50
Nov-05-25	Initiated	Piper Sandler	Overweight	$48
Mar-27-25	Initiated	JP Morgan	Overweight

Dec-08-25 07:45PM	ASH 2025 Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment (GlobeNewswire)
07:45PM	ASH 2025 Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP (GlobeNewswire)
07:45PM	ASH 2025 Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% (GlobeNewswire)
Dec-07-25 08:10PM	ASH 2025 Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances (GlobeNewswire)
Dec-06-25 10:15AM	Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
07:00PM	Loading…
Dec-04-25 07:00PM	Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA (GlobeNewswire) +7.10%
07:27AM	An Arch-backed biotech raises $53M to fight neurodegeneration (BioPharma Dive)
Dec-01-25 08:00AM	Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 (GlobeNewswire)
Nov-24-25 07:00PM	Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy (GlobeNewswire)
Nov-19-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 (GlobeNewswire)
Nov-05-25 09:51AM	Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 08:10PM	Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 (GlobeNewswire)
08:10PM	Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 (GlobeNewswire)
Oct-29-25 08:00PM	Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 (GlobeNewswire)
12:00PM	Loading…
Sep-01-25 12:00PM	Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-25-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 (GlobeNewswire) -9.23%
Aug-20-25 07:57PM	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates (GlobeNewswire)
Aug-19-25 04:20PM	Ascentage Pharmas Lisaftoclax Gets FDA/EMA Clearance (Exec Edge)
Aug-17-25 07:30PM	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA (GlobeNewswire)
Aug-07-25 08:00AM	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 (GlobeNewswire)
Aug-01-25 08:00AM	Ascentage Pharma to Participate in Evercore China Biotech Summit (GlobeNewswire)
Jul-23-25 08:00AM	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 (GlobeNewswire)
Jul-21-25 12:14AM	Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement (Insider Monkey)
Jul-17-25 04:30AM	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement (GlobeNewswire)
Jul-14-25 11:12AM	Ascentage Pharma's Novel Cancer Drug Approved in China (Insider Monkey) -5.33%
10:35AM	Ascentage Pharma Announces Pricing of Top-Up Placement (GlobeNewswire)
05:23AM	Ascentage Pharma Announces Proposed Top-Up Placement (GlobeNewswire)
Jul-10-25 12:55PM	Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug (Exec Edge)
09:30AM	Loading…
09:30AM	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL (GlobeNewswire)
Jul-08-25 11:58AM	Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance (Exec Edge)
Jul-07-25 07:30PM	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance (GlobeNewswire)
Jun-15-25 07:30PM	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL (GlobeNewswire)
Jun-09-25 07:30PM	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress (GlobeNewswire) +5.29%
Jun-02-25 07:30PM	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors (GlobeNewswire) +10.03%
07:30PM	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report (GlobeNewswire)
May-22-25 08:15PM	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 (GlobeNewswire)
May-11-25 05:20PM	Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
Apr-28-25 07:00AM	Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax (GlobeNewswire)
Apr-23-25 07:00PM	Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin (GlobeNewswire) +10.65% +6.69%
Apr-21-25 06:10PM	Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines (Exec Edge) +12.97%
07:00AM	Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines (GlobeNewswire)
Apr-02-25 01:07PM	Stocks To Watch In Gloomy Market Including This Breakout IPO (Investor's Business Daily)
Mar-27-25 07:00AM	Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates (GlobeNewswire) +9.96%
Mar-25-25 07:00PM	Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AAPG

Ascentage Pharma Group International ADR

Upgrade your FINVIZ experience